Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory DevelopmentSeeking Alpha • 10/23/24
Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025Business Wire • 10/22/24
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/06/24
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial ResultsBusiness Wire • 08/06/24
Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative DiseasesBusiness Wire • 08/06/24
Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and WebcastBusiness Wire • 07/30/24
Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy CandidateBusiness Wire • 07/24/24
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/09/24
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsBusiness Wire • 05/09/24
Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingBusiness Wire • 05/09/24
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastBusiness Wire • 05/02/24
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Business Wire • 04/22/24
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingBusiness Wire • 03/22/24
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire • 03/13/24
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPsBusiness Wire • 03/13/24
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and WebcastBusiness Wire • 03/12/24